$58.9 Million is the total value of Consonance Capital Management LP's 8 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 46.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TNDM | Sell | TANDEM DIABETES CARE INC | $17,133,000 | -62.1% | 147,327 | -51.0% | 29.07% | -1.5% |
| SLN | Sell | SILENCE THERAPEUTICS PLCads | $12,428,000 | -31.4% | 654,108 | -13.7% | 21.08% | +78.4% |
| SURROZEN INC | $10,527,000 | -52.9% | 3,497,500 | 0.0% | 17.86% | +22.4% | ||
| GMED | Sell | GLOBUS MED INCcl a | $7,896,000 | -70.7% | 107,024 | -71.3% | 13.40% | -23.8% |
| CMPX | COMPASS THERAPEUTICS INC | $4,743,000 | -57.5% | 3,500,000 | 0.0% | 8.05% | +10.5% | |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $4,407,000 | -65.9% | 24,563 | -59.0% | 7.48% | -11.4% |
| HLXA | Sell | HELIX ACQUISITION CORP | $1,521,000 | +2.5% | 137,000 | -8.7% | 2.58% | +166.5% |
| SURROZEN INC*w exp 08/01/203 | $291,000 | -78.1% | 1,165,832 | 0.0% | 0.49% | -43.1% | ||
| MSACW | Exit | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $0 | – | -33,331 | -100.0% | -0.02% | – |
| CMAXW | Exit | CAREMAX INC*w exp 06/08/202 | $0 | – | -45,960 | -100.0% | -0.04% | – |
| PANA | Exit | PANACEA ACQUISITION CORP II | $0 | – | -200,000 | -100.0% | -1.26% | – |
| Exit | ARYA SCIENCES ACQUISITN CORP | $0 | – | -300,000 | -100.0% | -1.90% | – | |
| MSAC | Exit | MEDICUS SCIENCES ACQUISITION | $0 | – | -300,000 | -100.0% | -1.90% | – |
| JYAC | Exit | JIYA ACQUISITION CORP | $0 | – | -300,000 | -100.0% | -1.91% | – |
| RACB | Exit | RESEARCH ALLIANCE CORP II | $0 | – | -300,000 | -100.0% | -1.91% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.